Transparency Market Research (TMR) has published a new report titled, “Psoriatic Arthritis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global psoriatic arthritis therapeutics market was valued at US$ 6,011.7 Mn in 2017. It is projected to expand at a CAGR of 11.4% from 2018 to 2026. High prevalence of psoriatic arthritis, large unmet medical needs, and new product approvals are anticipated to drive the global market in the next few years. North America is expected to dominate the global psoriatic arthritis therapeutics market during the forecast period, followed by Europe. Potential unmet medical needs for moderate to severe psoriatic arthritis, increase in adoption of biologic drugs, and approvals of new therapeutic drug classes in the U.S. and Europe are likely to drive the psoriatic arthritis therapeutics market in these regions during the forecast period. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period.
Planning To Lay Down Future Strategy? Request Brochure Of Psoriatic Arthritis Therapeutics Market
High prevalence and increase in incidence rate of psoriatic arthritis to drive market
High prevalence and rise in incidence rate of psoriatic arthritis across the globe is a key factor driving the global psoriatic arthritis therapeutics market. Chances of developing psoriatic arthritis among patients with psoriasis is high, and the number of patients with psoriatic arthritis has been increasing significantly in the last few years. According to the International Federation of Psoriasis Association, more than 125 million people were affected with psoriasis, globally, in 2015. It is estimated that between 10% and 30% of patients with psoriasis tend to develop psoriatic arthritis. According to the study published in the Journal of the American Academy of Dermatology, in 2013, Denmark had the highest prevalence rate of psoriatic arthritis, with around 42% prevalence rate, while the lowest prevalence rates were recorded in Canada and Belgium. Thus, the high prevalence and substantial rise in incidence rate of psoriasis and psoriasis-led psoriatic arthritis across globe is a key factor driving the global psoriatic arthritis therapeutics market.
Request For Covid19 Impact Analysis –
Interleukin inhibitors and PDE4 inhibitors drugs to propel the psoriatic arthritis therapeutics market
The report offers a detailed segmentation of the global psoriatic arthritis therapeutics market based on different therapeutic drug classes approved and commercialized for psoriatic arthritis. Based on drug class, the global market has been segmented into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Interleukin inhibitors drugs have evolved as new therapeutic drug class for the treatment of psoriatic arthritis when other therapeutic drugs classes, especially TNF alpha inhibitors, fail to relieve the symptoms of psoriatic arthritis. Interleukin inhibitor drugs, especially IL-17A inhibitor drugs, have shown the highest clinical efficacy, as compared to any other biologic drug available, to relive the symptoms of psoriatic arthritis.